Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with/without Exablate MRgFUS in Recurrent Glioblastoma
NCT05879120Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2024
- Primary completion
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in glioblastoma (GBM) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Overall Survival and Intratumoral Effector T-cell Infiltration. Planned start Jul 2024; status: withdrawn.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05879120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05879120.